Revinova Names Kiran Nataraj as Chief Commercial Officer

MALBOROUGH, MA, UNITED STATES, October 5, 2026 /CourierPR/ -- Revinova, an enterprise AI agent and learning platform for the clinical trial industry, has appointed Kiran Nataraj, Ph.D., as its Chief Commercial Officer. This move aims to drive the adoption of AI agents in clinical trials, leveraging Nataraj's extensive experience in the life sciences sector.

Nataraj joins Revinova from RQM+, a full-service contract research organization (CRO), where he served as Senior Director of Business Development. His previous roles at Syneos Health and AMRA Medical, where he led sales of imaging biomarker and clinical data analytics solutions, further underscore his expertise in complex, long-cycle solutions. Prior to these positions, Nataraj held senior sales roles at PerkinElmer and Olympus Scientific Solutions, supporting preclinical and drug discovery research. His early career was spent as a neuroscientist at Brandeis University, where he published peer-reviewed research in prestigious journals such as Nature, Neuron, and the Journal of Neuroscience.

Revinova's platform is designed to turn approved standard operating procedures (SOPs), protocols, and training content into AI-powered learning experiences and agents. These agents surface trusted answers from company-approved content, supporting faster site activation, consistent protocol training across global sites, and ongoing learning reinforcement throughout the study lifecycle. The platform runs on AWS Bedrock and is SOC 2 Type II and HIPAA certified.

Nataraj brings more than 15 years of commercial experience in the life sciences, most of it selling complex, long-cycle solutions to pharmaceutical, biotech, and medtech sponsors and CROs. His appointment is expected to bolster Revinova's efforts to expand its market reach and enhance its position in the clinical trial industry.

Revinova, headquartered in Marlborough, Massachusetts, is an enterprise AI agent and learning platform for the clinical trial industry. Its solution supports faster site activation, more consistent protocol training across global sites, and ongoing learning reinforcement throughout the study lifecycle. The platform combines an LMS with agentic AI, runs on AWS Bedrock, and is SOC 2 Type II and HIPAA certified.